PRNewsWire
24 Oct 2025, 13:00 UTC · 47w ago
Verdict
Headline takes no side. We score BAX −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Baxter's Novum LVP product allegedly suffers from systemic defects causing malfunctions including underinfusion, overinfusion, and non-delivery of fluids.
More negative than 99% of claims this week
Baxter is facing a class action securities lawsuit alleging it concealed device malfunctions, injuries, and deaths associated with the Novum LVP.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 95% of claims this week
There is a reported risk that customers will be instructed to take existing Novum LVPs out of service and that Baxter may pause all new sales of these pumps.
So whatA total sales pause and product withdrawal would directly impair near-term growth and market share.
More negative than 91% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit alleging securities fraud and systemic defects in its Novum LVP product.
More negative than 86% of ticker scores this week
The company experienced a sharp share-price decline following its Q2 2026 revenue results.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
10h ago
+1.9%
Price is moving against the score
$23.43 vs $22.99 close before publication (Oct 23) · not market-adjusted
BAX chart →
